Exploring new cancer treatment targets for acute myeloid leukemia.
Structural surfaceomics to probe conformation-selective immunotherapy targets
This study is exploring new ways to treat acute myeloid leukemia (AML) by finding special proteins on cancer cells that can be targeted by a type of immune therapy, which could lead to safer and more effective treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10904543 on NIH RePORTER |
What this research studies
This research investigates innovative immunotherapy targets for acute myeloid leukemia (AML) by utilizing a novel technology called structural surfaceomics. This approach focuses on identifying unique, cancer-specific conformations of plasma membrane proteins that can serve as effective targets for treatment. By analyzing AML models and validating findings with patient samples, the research aims to develop engineered T-cell therapies that specifically target these proteins, potentially leading to safer and more effective treatment options for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who do not have acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new, more effective immunotherapy for patients with acute myeloid leukemia, improving treatment outcomes and reducing side effects.
How similar studies have performed: This approach is innovative and has not been widely tested in previous research, making it a novel exploration in the field of cancer immunotherapy.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wiita, Arun P. — University of California, San Francisco
- Study coordinator: Wiita, Arun P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.